阿霉素洗脱微球TACE对比传统TACE治疗肝癌的Meta分析（英文）  

Doxorubicin-eluting beads vs conventional TACE for hepatocellular carcinoma: a Meta-analysis

作　　者：周寨文[1] 王子豫 陈清莲 黄俊海[3] ZHOU Zhaiwen;WANG Ziyu;CHEN Qinlian;HUANG Junhai(Department of Radiology,the First Affiliated Hospital of Guangzhou University of Chinese Medicine,Guangzhou 510405,China;the First Clinical Medical School of Guangzhou University of Chinese Medicine,Guangzhou 510405,China;Department of Hepatobiliary Surgery,the First Affiliated Hospital of Guangzhou University of Chinese Medicine,Guangzhou 510405,China)

机构地区：[1]广州中医药大学第一附属医院放射科,广东广州510405 [2]广州中医药大学第一临床医学院,广东广州510405 [3]广州中医药大学第一附属医院肝胆外科,广东广州510405

出　　处：《中国医学物理学杂志》2019年第2期239-244,共6页Chinese Journal of Medical Physics

基　　金：Supported by National Natural Science Foundation of China(81873303)~~

摘　　要：目的:采用Meta分析方法评价和比较阿霉素洗脱微球TACE(DEB-TACE)与传统TACE(C-TACE)治疗肝癌的有效性和安全性。方法:从Pub Med、Web of Science和CKIN数据库检索DEB-TACE和C-TACE治疗肝癌的文献。分别采用Rev Man5.0软件分析肿瘤反应和不良事件,漏斗图分析出版偏倚。结果:共有13个研究1 325例肝癌患者纳入分析。DEBTACE组的肿瘤反应率优于C-TACE组(OR:2.28;95%CI[1.75, 2.96];P<0.0010)。DEB-TACE组的不良事件风险低于CTACE组(RR:0.56;95%CI[0.32, 0.97];P=0.04)。结论:和C-TACE对比,DEB-TACE治疗肝癌更有效、不良事件风险更低。Objective To conduct a Meta-analysis for assessing the therapeutic efficacy and safety of doxorubicin-eluting bead transcatheter arterial chemoembolization(DEB-TACE)vs conventional TACE(C-TACE)in the treatment of hepatocellular carcinoma(HCC).Methods The relevant studies on DEB-TACE and C-TACE for HCC were searched from PubMed,Web of Science and CKIN databases.The tumor responds and adverse events in the selected studies were analyzed with RevMan5.0 statistical software.Moreover,publication bias was assessed by a funnel plot.Results Thirteen studies with 1 325 HCC patients were finally included in this analysis.The tumor response to DEB-TACE was better than that to C-TACE(OR:2.28;95%CI[1.75,2.96];P<0.001 0).The risk of adverse events in DEB-TACE group was also lower than that in C-TACE group(RR:0.56;95%CI[0.32,0.97];P=0.04).Conclusion Compared with C-TACE,DEB-TACE is more effective and has lower risk of adverse events in the treatment of HCC.

关 键 词：肝癌 药物洗脱微球TACE META分析 疗效 

分 类 号：R735.7[医药卫生—肿瘤]